This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the potential of remyelination and neuronal repair in multiple sclerosis patients following treatment with CNM-Au8® 30 mg and the results from the VISIONARY-MS Trial

Ticker(s): CLNN

Who's the expert?

Institution: University of California Irvine

  • Associate Professor of Clinical Neurology at UC Irvine.
  • Treats 500 patients with MS .
  • Clinical interests are in autoimmune diseases, multiple sclerosis, demyelinating neuropathies.
  • Currently involved in translational research and clinical trials studying demyelinating autoimmune disease of the central nervous system.

Interview Goal
to discuss the current standard of care and the potential of CNM-Au8, a treatment being developed by Clene Nanomedicine for repair and remyelination in multiple sclerosis.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.